giovedì, 3 dicembre 2020
28 Agosto 2018

FDA Grants SL-401 Priority Review for Rare Hematologic Cancer

August 13, 2018 – The FDA has granted a priority review designation to a biologics license application (BLA) for SL-401 (tagraxofusp) for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to Stemline Therapeutics, the developer of the novel stemness inhibitor. The drug is directed at the IL-3 receptor, which is overexpressed on cancer stem cells and/or tumor bulk in many hematologic malignancies. SL-401 is being investigated as … (leggi tutto)